The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

BIM-23014 C     (2S)-6-amino-N-[(1S)-1- [[(1S)-1-[[(1S,2R)...

Synonyms: LS-172215, Bim 23014 C, AC1L3ON5, C54H71N11O10S2, 113294-82-9, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Angiopeptin


High impact information on Angiopeptin

  • Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model [5].
  • This study evaluated the efficacy and the optimal mode of administration of angiopeptin, a somatostatin analogue with antiproliferative activity, in a porcine coronary in-stent restenosis model [5].
  • The aim of this study was to analyze the effect of angiopeptin pretreatment on the level of expression of the c-fos and c-jun protooncogenes, early markers of smooth muscle cell proliferation, after balloon denudation of rabbit aorta [6].
  • CONCLUSIONS: Our results show that the inhibitory effect of angiopeptin on neointimal thickening is related to events that occur very early after injury and suggest that the inhibition of smooth muscle cell activation may be responsible, at least in part, for this effect [6].
  • In addition, we provide data to suggest that the long-acting somatostatin analogues octreotide and angiopeptin inhibit IGF-I- and basic fibroblast growth factor (b-FGF)- induced human coronary artery SMC proliferation [7].

Chemical compound and disease context of Angiopeptin


Biological context of Angiopeptin


Anatomical context of Angiopeptin


Associations of Angiopeptin with other chemical compounds

  • In contrast, angiopeptin, triptorelin and TRH exhibited a K(1) of 4.0 x 10(6), 5.3 x 10(6) and 20.2 x 10(6)M(-1), respectively, and a K(2) of 0.4 x 10(6), 0.5 x 10(6) and 1.4 x 10(6)M(-1), respectively [12].
  • The x-reciprocal and the double-reciprocal plots indicated the presence of two portions of straight lines for angiopeptin, triptorelin and the thyrotropin releasing hormone (TRH), and therefore the probable existence of a second-order interaction which causes the deviation from the 1:1 model [12].
  • 4. Inhibition of MEK1 or Src, but not PKA, PI 3-kinases or tyrosine kinases, by reportedly selective inhibitors reduced sst(2)-mediated responses by somatostatin, but not angiopeptin [13].
  • Inhibition of vascular cell proliferation by angiopeptin was evaluated by tritiated thymidine incorporation into the balloon-injured rabbit aorta [14].
  • Solution conformation by NMR and molecular modeling of three sulfide-free somatostatin octapeptide analogs compared to angiopeptin [15].

Gene context of Angiopeptin


Analytical, diagnostic and therapeutic context of Angiopeptin


  1. The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after balloon injury in the rabbit. Hong, M.K., Bhatti, T., Matthews, B.J., Stark, K.S., Cathapermal, S.S., Foegh, M.L., Ramwell, P.W., Kent, K.M. Circulation (1993) [Pubmed]
  2. Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Emanuelsson, H., Beatt, K.J., Bagger, J.P., Balcon, R., Heikkilä, J., Piessens, J., Schaeffer, M., Suryapranata, H., Foegh, M. Circulation (1995) [Pubmed]
  3. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. Lundergan, C.F., Foegh, M.L., Ramwell, P.W. J. Am. Coll. Cardiol. (1991) [Pubmed]
  4. The somatostatin analog angiopeptin does not reduce chronic hypoxic pulmonary hypertension in rats. Sidney, E.J., Hampl, V., Nelson, D.P., Archer, S.L., Foegh, M.L., Cathapermal, S.S., Weir, E.K. Proc. Soc. Exp. Biol. Med. (1996) [Pubmed]
  5. Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. Hong, M.K., Kent, K.M., Mehran, R., Mintz, G.S., Tio, F.O., Foegh, M., Wong, S.C., Cathapermal, S.S., Leon, M.B. Circulation (1997) [Pubmed]
  6. Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation. Bauters, C., Van Belle, E., Wernert, N., Delcayre, C., Thomas, F., Dupuis, B., Lablanche, J.M., Bertrand, M.E., Swynghedauw, B. Circulation (1994) [Pubmed]
  7. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Grant, M.B., Wargovich, T.J., Ellis, E.A., Caballero, S., Mansour, M., Pepine, C.J. Circulation (1994) [Pubmed]
  8. Angiopeptin inhibition of myointimal hyperplasia after balloon angioplasty of large arteries in hypercholesterolaemic rabbits. Howell, M.H., Adams, M.M., Wolfe, M.S., Foegh, M.L., Ramwell, P.W. Clin. Sci. (1993) [Pubmed]
  9. Disposition and tissue distribution of angiopeptin in the rat. Cathapermal, S.S., Foegh, M.L., Rau, C.S., Ramwell, P.W. Drug Metab. Dispos. (1991) [Pubmed]
  10. Angiopeptin inhibits intimal hyperplasia after angioplasty in porcine coronary arteries. Santoian, E.D., Schneider, J.E., Gravanis, M.B., Foegh, M., Tarazona, N., Cipolla, G.D., King, S.B. Circulation (1993) [Pubmed]
  11. Somatostatin receptor subtype expression and function in human vascular tissue. Curtis, S.B., Hewitt, J., Yakubovitz, S., Anzarut, A., Hsiang, Y.N., Buchan, A.M. Am. J. Physiol. Heart Circ. Physiol. (2000) [Pubmed]
  12. A study of the binding between polymers and peptides, using affinity capillary electrophoresis, applied to polymeric drug delivery systems. Progent, F., Taverna, M., Le Potier, I., Gopée, F., Ferrier, D. Electrophoresis (2002) [Pubmed]
  13. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Alderton, F., Fan, T.P., Humphrey, P.P. Br. J. Pharmacol. (2001) [Pubmed]
  14. Early inhibition of myointimal proliferation by angiopeptin after balloon catheter injury in the rabbit. Foegh, M.L., Asotra, S., Conte, J.V., Howell, M., Kagan, E., Verma, K., Ramwell, P.W. J. Vasc. Surg. (1994) [Pubmed]
  15. Solution conformation by NMR and molecular modeling of three sulfide-free somatostatin octapeptide analogs compared to angiopeptin. Hennig, P., Raimbaud, E., Thurieau, C., Volland, J.P., Michel, A., Fauchère, J.L. J. Comput. Aided Mol. Des. (1996) [Pubmed]
  16. Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. Alderton, F., Fan, T.P., Schindler, M., Humphrey, P.P. Br. J. Pharmacol. (1998) [Pubmed]
  17. Differential effects of somatostatin and angiopeptin on cell proliferation. Alderton, F., Lauder, H., Feniuk, W., Fan, T.P., Humphrey, P.P. Br. J. Pharmacol. (1998) [Pubmed]
  18. Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis. Serruys, P.W. Circulation (1995) [Pubmed]
WikiGenes - Universities